CFDE Data Portal | Search IRAG2

	Label	Description
	IRAG2 Gene (Entity type)	ENSG00000118308 - inositol 1,4,5-triphosphate receptor associated 2
	IRAG2 HUMAN Protein (Entity type)	Inositol 1,4,5-triphosphate receptor associated 2
	IRAG2 MOUSE Protein (Entity type)	Inositol 1,4,5-triphosphate receptor associated 2
	GSE135350 2 V 4 DEXAMETHASONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE110178 2 V 3 TRANYLCYPROMINE MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE77108 8 V 7 SAHA HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE212231 GSE218491 SHP2 inhibition 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE205976 GSE205978 CEP83 knockout TIME 1 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE159678 4 V 2 CHLOROQUINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE189035 inositol 2 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS

IRAG2

ENSG00000118308 - inositol 1,4,5-triphosphate receptor associated 2

IRAG2 HUMAN

Inositol 1,4,5-triphosphate receptor associated 2

IRAG2 MOUSE

Inositol 1,4,5-triphosphate receptor associated 2

GSE135350 2 V 4 DEXAMETHASONE HUMAN UP

A Gene Set from LINCS

GSE110178 2 V 3 TRANYLCYPROMINE MOUSE DN

A Gene Set from LINCS

GSE77108 8 V 7 SAHA HUMAN DN

A Gene Set from LINCS

GSE212231 GSE218491 SHP2 inhibition 3 v 5 human up

A Gene Set from LINCS

GSE205976 GSE205978 CEP83 knockout TIME 1 v 4 human dn

A Gene Set from LINCS

GSE159678 4 V 2 CHLOROQUINE HUMAN UP

A Gene Set from LINCS

GSE189035 inositol 2 v 4 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.